The U.S. Food and Drug Administration on Tuesday approved Ajovy, an injection made by Israeli drugmaker Teva Pharma , to help ...

The US Food and Drug Administration (FDA) has approved a label expansion to Teva’s Ajovy in certain children and adolescents, ...

FDA approves single-dose AJOVY® (fremanezumab-vfrm) injection for the preventive treatment of episodic migraine in children ...

The FDA has approved Ajovy (fremanezumab) for the prevention of episodic migraine in pediatric patients aged 6 to 17 years weighing at least 45kg.

Ajovy becomes the first-and-only calcitonin gene-related peptide agonist approved for pediatric patients aged six to 17 years ...

Teva Pharmaceutical has received a green light from the US regulator for its biologic Ajovy (fremanezumab) to be used for ...

Parsippany: Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd., has announced that the U.S. Food ...

Teva (TEVA) stock in focus as the FDA expands label for its migraine therapy Ajovy for children and adolescents aged 6–17 years. Read more here.

The FDA expanded the indication for fremanezumab (Ajovy) injection for episodic migraine prevention to include children and ...

Reported EPS is $0.2429 EPS, expectations were $0.63. Operator: Hello, and welcome to the Teva Pharmaceutical Industries ...

Teva (TEVA) stock in focus as the company posts mixed Q2 2025 results amid its underperforming generic drugs. Read more here.